Biosergen AB: BioStock: Biosergen scales up for future wins
Biosergen is charging into 2025 with momentum, building on a transformative 2024 that showcased the life-saving potential of its antifungal drug candidate, BSG005. As the biotech company continues its mission to combat the global crisis of life-threatening fungal infections, it is focused on key strategic priorities for the year ahead expanding clinical trials, accelerating development, and strengthening its global presence.
Read the article at biostock.se:
https://www.biostock.se/en/2025/03/biosergen-scales-up-for-future-wins/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/